Cite
HARVARD Citation
Hanley, M. et al. (2018). A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. Journal of clinical pharmacology. pp. 114-121. [Online].